Inclusion Criteria:

- Patients diagnosed with solid tumour but which have no standard treatment or did not
respond to previous treatments.

- Patients who usually have mild symptoms capable of walking and light and sedentary
work.

- Patients who can stay in hospital at least during 4 weeks.

Exclusion Criteria:

- Patients who have received treatment with anti-cancer agent within 4 weeks prior to
first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.

- Patients with abnormally low levels of neutrophil count, platelet count, or
haemoglobin, indicators of bone marrow function.

- Patients who received therapeutic radiotherapy at central nervous system within 3
months prior to first dose of study treatment; the other sites within 4 weeks; or
local site within 2 weeks.